XERS Stock Analysis: Xeris Pharmaceuticals | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 1.847m USD | 12M Return: 28% | US98422E1038 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 23.7M
Qual. Beats: -1
Rev. Trend: 99.4%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 8.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Xeris Biopharma Holdings, Inc. (XERS) is a commercial-stage biopharmaceutical company headquartered in Chicago, Illinois, focused on developing and commercializing therapies for chronic endocrine and neurological diseases. The company was incorporated in 2005 and has been listed on NASDAQ since its IPO in June 2018, currently operating with a small-cap market capitalization in the U.S. healthcare sector. As a commercial-stage biopharmaceutical firm, Xeris generates revenue from approved products while also advancing a pipeline candidate through clinical development.
The companys commercial portfolio includes Gvoke, a ready-to-use liquid glucagon for severe hypoglycemia; Keveyis, for primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for endogenous Cushings syndrome. In addition, Xeris is developing XP-8121, a once-weekly subcutaneous levothyroxine injection currently in Phase 3 clinical trials for hypothyroidism. Specialty biopharmaceutical companies operating in rare and chronic disease areas typically depend on a small number of approved products, making pipeline progression and regulatory approvals critical to long-term growth.
- Gvoke glucagon sales growth competes with Baqsimi in hypoglycemia market
- Recorlev launch accelerates in Cushings syndrome treatment
- XP-8121 phase 3 hypothyroidism data readout approaches
| Net Income: -17.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 18.46 > 1.0 |
| NWC/Revenue: 25.40% < 20% (prev 36.75%; Δ -11.35% < -1%) |
| CFO/TA 0.14 > 3% & CFO 56.6m > Net Income -17.2m |
| Net Debt (204.5m) to EBITDA (16.4m): 12.46 < 3 |
| Current Ratio: 1.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (172.8m) vs 12m ago 10.80% < -2% |
| Gross Margin: 83.34% > 18% (prev 81.14%; Δ 2.21% > 0.5%) |
| Asset Turnover: 89.85% > 50% (prev 73.51%; Δ 16.34% > 0%) |
| Interest Coverage Ratio: 0.14 > 6 (EBIT TTM 3.93m / Interest Expense TTM 28.3m) |
| A: 0.21 (Total Current Assets 274.8m - Total Current Liabilities 189.6m) / Total Assets 411.9m |
| B: -1.70 (Retained Earnings -700.2m / Total Assets 411.9m) |
| C: 0.01 (EBIT TTM 3.93m / Avg Total Assets 373.3m) |
| D: -0.02 (Book Value of Equity -9.73m / Total Liabilities 421.6m) |
| Altman-Z'' = -4.14 = D |
| DSRI: 0.80 (Receivables 58.1m/53.0m, Revenue 335.4m/246.0m) |
| GMI: 0.97 (GM 81.14% / 83.34%) |
| AQI: 0.74 (AQ_t 0.27 / AQ_t-1 0.36) |
| SGI: 1.36 (Revenue 335.4m / 246.0m) |
| TATA: -0.18 (NI -17.2m - CFO 56.6m) / TA 411.9m) |
| Beneish M = -3.12 (Cap -4..+1) = AA |
As of October 12, 2026, the stock is trading at USD 10.48 with a total of 2,995,227 shares traded. Over the past week, the price has changed by +15.42%, over one month by +35.93%, over three months by +21.58% and over the past year by +27.96%.
Current recommended Stop Loss: 9.80 (which is 6.5% or 1.3 ATR below the current price).
Xeris Pharmaceuticals has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy XERS.
- StrongBuy: 5
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12.6 | 19.9% |
P/E Forward = 36.9004
P/S = 5.5063
P/B = 107.6774
Revenue TTM = 335.4m USD
EBIT TTM = 3.93m USD
EBITDA TTM = 16.4m USD
Long Term Debt = 188.8m USD (from longTermDebt, last quarter)
Short Term Debt = 70.1m USD (from shortTermDebt, last quarter)
Debt = 326.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 36.9m
Net Debt = 204.5m USD (calculated: Debt 326.3m - CCE 121.7m)
Enterprise Value = 2.05b USD (1.85b + Debt 326.3m - CCE 121.7m)
Interest Coverage Ratio = 0.14 (Ebit TTM 3.93m / Interest Expense TTM 28.3m)
EV/FCF = 37.04x (Enterprise Value 2.05b / FCF TTM 55.4m)
FCF Yield = 2.70% (FCF TTM 55.4m / Enterprise Value 2.05b)
FCF Margin = 16.51% (FCF TTM 55.4m / Revenue TTM 335.4m)
Net Margin = -5.12% (Net Income TTM -17.2m / Revenue TTM 335.4m)
Gross Margin = 83.34% ((Revenue TTM 335.4m - Cost of Revenue TTM 55.9m) / Revenue TTM)
Gross Margin QoQ = 86.41% (prev 84.02%)
Tobins Q-Ratio = 4.98 (Enterprise Value 2.05b / Total Assets 411.9m)
Interest Expense / Debt = 8.66% (Interest Expense 28.3m / Debt 326.3m)
Taxrate = 0.0% (0.0 / 554k)
NOPAT = 3.93m (EBIT 3.93m * (1 - 0.00%))
Current Ratio = 1.45 (Total Current Assets 274.8m / Total Current Liabilities 189.6m)
Debt / Equity = -33.52 (negative equity) (Debt 326.3m / totalStockholderEquity, last quarter -9.73m)
Debt / EBITDA = 12.46 (Net Debt 204.5m / EBITDA 16.4m)
Debt / FCF = 3.69 (Net Debt 204.5m / FCF TTM 55.4m)
Total Stockholder Equity = 4.03m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.60% (Net Income -17.2m / Total Assets 411.9m)
RoE = -426.3% (Net Income TTM -17.2m / Total Stockholder Equity 4.03m)
RoCE = 2.04% (EBIT 3.93m / Capital Employed (Equity 4.03m + L.T.Debt 188.8m))
RoIC = 1.43% (NOPAT 3.93m / Invested Capital 275.7m)
WACC = 8.03% (E(1.85b)/V(2.17b) * Re(7.92%) + D(326.3m)/V(2.17b) * Rd(8.66%) * (1-Tc(0.0)))
Discount Rate = 7.92% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.75 | Cagr: 9.63%
[DCF] Terminal Value 75.44% ; FCFF base≈55.4m ; Y1≈55.6m ; Y5≈58.9m
[DCF] Fair Price = 3.90 (EV 916.2m - Net Debt 204.5m = Equity 711.6m / Shares 182.3m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.38 | # QB: -1
Revenue Correlation: 99.38 | Revenue CAGR: 34.30% | SUE: 0.90 | # QB: 2
EPS current Quarter (2026-09-30): EPS=-0.06 | Chg30d=N/A | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=0.03 | Chg30d=N/A | Revisions=-50% | GrowthEPS=+0.0% | GrowthRev=+32.9%
EPS next Year (2027-12-31): EPS=0.44 | Chg30d=+12.82% | Revisions=+50% | GrowthEPS=+1660.0% | GrowthRev=+23.8%
[Analyst] Revisions Ratio: +0% (up=4, down=4)